Jump to content

LaurenH

Administrators
  • Posts

    795
  • Joined

  • Last visited

  • Days Won

    27

Posts posted by LaurenH

  1. Hi, M,

    Welcome to LCSC. We've been thinking about you and your mom. How are you both doing? This community is a great place to connect with survivors and other caregivers who are going through similar situations. Please let us know if you have any questions or would like more information about LUNGevity's support and survivorship programs. We hope to hear from you soon.

    With gratitude,

    Lauren
    --
    Digital Community Manager
    LUNGevity Foundation

  2. Hi, Kaly,

    Welcome to LCSC. We hope to hear from you again soon with an update on how you and your brother are doing. I know the distance must be very difficult. He is fortunate to have people who love him all over the world. Please let us know if you have questions or would like resources/information on a particular topic. We are here for you!

    Lauren
    --
    Digital Community Manager
    LUNGevity Foundation

  3. Hi, Sandra,

    Welcome to LCSC. I am happy that you've already connected with some of our members. We are here to support you and help you find information and resources to help you navigate lung cancer. Please feel free to ask questions, join in the ongoing conversations on the discussion boards, and let us know if you'd like more information about LUNGevity's support and survivorship programs.

    With gratitude,

    Lauren
    --
    Digital Community Manager
    LUNGevity Foundation

  4. A clinical trial is a type of research study that tests how well medical approaches—screening, prevention, diagnosis, or treatment—work in people. Clinical trials can provide access to new approaches to lung cancer patients. However, most lung cancer patients do not participate in clinical trials. Please complete this survey about clinical trials by answering from your personal experience. The survey is 100% anonymous. THANK YOU for your time!

    Survey for Survivors: https://www.surveymonkey.com/r/Survivor_Clinical_Trial_2017

    Survey for Caregivers:  https://www.surveymonkey.com/r/Caregiver_Clinical_Trial_2017

     

  5. Hi, Mommy's girl,

    Welcome to LCSC. I am sorry that you and your family are going through this. I hope you can connect with many other caregivers and lung cancer patients in this community who can share their personal experiences. I put out a call to respond to your post on some of our other social media private groups. I encouraged anyone with information or experience with Tarceva and kidney dialysis to respond to this thread.

    Please let me know if you would like additional resources or information about lung cancer or targeted therapy or if you'd like to learn more about our support programs and I will be happy to help.

    Lauren
    --
    Digital Community Manager
    LUNGevity Foundation

  6. LUNGevity Foundation, the nation’s preeminent lung cancer research foundation, today announced that Alice T. Shaw, MD, PhD, has joined LUNGevity’s Scientific Advisory Board, a group of 20 world-renowned scientists and researchers that guides LUNGevity’s research program. The Scientific Advisory Board is integral to the Foundation, overseeing the scientific strategy and ensuring that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives of lung cancer survivors. 

    LUNGevity is the only lung cancer organization with a programmatic focus on early detection and Career Development Awards. Our researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The research program is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer.

    Dr. Shaw is the Director of the Center for Thoracic Cancers and the Paula O’Keeffe Endowed Chair of Thoracic Oncology at Massachusetts General Hospital. She is also an Associate Professor of Medicine at Harvard Medical School. In addition to caring for patients with lung cancer, Dr. Shaw performs clinical and translational research. Her clinical research focuses on subsets of NSCLC that have unique driver mutations, such as EGFR, ALK, and ROS1. Her translational research focuses on understanding and making clear the mechanisms of resistance to targeted therapies; she is currently developing novel combination treatment strategies. Her research has helped to develop numerous FDA-approved targeted therapies for patients with oncogene-driven NSCLC, such as crizotinib (Xalkori®) for patients with ALK or ROS1 rearrangements.

    “We could not be happier that Dr. Shaw has joined our Scientific Advisory Board,” said Andrea Ferris, President and Chairman of LUNGevity Foundation. “She is a brilliant thinker, an innovator, and a compassionate advocate for her patients. In particular, her groundbreaking work that led to the development of Xalkori® has extended and improved the lives of many NSCLC patients. Her expertise and counsel will advance LUNGevity’s goal to increase and improve survivorship for those affected by lung cancer.”

    Read the full press release here.

  7. Hi, Lisa,

    Welcome to LCSC. I will reach out to some of our members with ROS1 and encourage them to introduce themselves to you in this threat. This site is a great place to connect with others navigating a similar diagnosis and to learn from their experiences. In the meantime, please feel free to explore the discussion boards and join in any conversation that resonates with you.

    With gratitude,

    Lauren
    --
    Digital Community Manager
    LUNGevity Foundation

  8. Hi, Laura,

    Welcome to LCSC. This site is a great place to connect with others navigating a lung cancer diagnosis and to find resources and information. There have been several breakthroughs in research in the past few years and there are more treatment options in the pipeline. If you're comfortable sharing the results of your tests this week, some of our veteran members may be able to provide some insight and encouragement based on their own experiences. I am also happy to provide you with information about LUNGevity's support resources. Please know that you are not alone and that we are here for you.

    With gratitude,

    Lauren
    --
    Digital Community Manager
    LUNGevity Foundation 

  9. Hi, Tony,

    Welcome to LCSC. I hope that you make many meaningful connections with other members on this site. This is a great place to ask questions and get support. Tom has already provided links to information about immunotherapy and checkpoint inhibitors. I am happy to help you find additional resources and support. Please feel free to post any questions or join some of the ongoing conversations in the discussion boards.

    With gratitude,

    Lauren
    --
    Digital Community Manager
    LUNGevity Foundation

  10. Susan, thank YOU for all you do for the members of this community! You are such a positive presence and I am especially grateful for the lengths you take to welcome people to this site and help them feel like they are not alone. I am very glad that you joined LCSC and that you continue to be a source of hope, strength, and support for all of us.

    With gratitude,

    Lauren
    --
    Digital Community Manager
    LUNGevity Foundation

  11. Hi, Brenda,

    Welcome to LCSC. I am happy to see that you've already connected with Tom and Susan. As Tom mentioned, there have been many breakthroughs in research and treatment that are improving quality of life and survivorship. Please feel free to post your questions and explore some of the discussions on this site. You're welcome to join in on any of the conversations or start new topics that are personally relevant to you.

    I am happy to help you find additional resources and support if you'd like. In the meantime, please know that we are here for you!

    With gratitude,

    Lauren
    --
    Digital Community Manager
    LUNGevity Foundation

  12. Hi, Carl,

    Welcome to LCSC. I am glad to see that you've met several of our members already. This site is a great place to share your experiences and learn from others experiences and connect with people who are also living with a lung cancer diagnosis. If you have any questions before your appointment next month, please feel free to share them in the forums. Tom also writes an excellent blog for this site.

    If you are looking for resources on a particular topic, I am happy to help. LUNGevity's Lung Cancer 101 site is a great place to start.

    With gratitude,

    Lauren
    --
    Digital Community Manager
    LUNGevity Foundation

  13.  LUNGevity Foundation has launched Patient FoRCe, the first-ever critical bridge to connect the voices of lung cancer patients — a significant population — with health care professionals, regulators, policymakers, and developers of drugs. “Lung cancer is the #1 cancer killer, taking the lives of 157,000 Americans every year. LUNGevity is leading the way in changing the paradigm of cancer treatment ─ from assuming patient wishes to evidence-based conclusions about what patients value,” said LUNGevity Chairman Andrea Stern Ferris. “Through Patient FoRCe, lung cancer patient voices will be heard and heeded as policy is developed, research is conducted, and treatment decisions are made.”

    Patient FoRCe, LUNGevity’s Patient-Focused Research Center, will undertake never-before studies of those living with lung cancer, collecting and sharing robust qualitative and quantitative data about lung cancer patients’ preferences and experiences to inform treatment, as well as relevant policy and research protocols.  

    Patient FoRCe’s immediate focus will include continuing a study of patient preferences and experiences regarding access to care, treatment and diagnostic options, and the impact of symptoms on daily living, as well as conducting studies to facilitate patients’ access to biomarker testing, which is essential to implementing precision medicine. Patient FoRCe will also initiate a study into increasing adherence to lung cancer screening protocols for people at high risk for lung cancer.  Additional projects will be based on stakeholder input and the guidance of an external advisory board of survivors, academic and community clinicians, industry partners, patient advocacy groups, and community partners.

    LUNGevity formally announced Patient FoRCe at the American Association for Cancer Research’s 2017 Annual Meeting in Washington, DC, on Sunday, April 2. Andrea Stern Ferris spoke to the urgency of the initiative, saying, “For too long, public policy, the practice of medicine, and drug development have not adequately integrated the viewpoint of patients. LUNGevity is determined to change that paradigm. By incorporating the patient’s voice into every step of the process – in policymaking, in trials, in treatments – we will improve outcomes for those diagnosed with lung cancer.” 

    “Our goal is to uncover gaps in information, misperceptions about patient attitudes, and areas of unmet patient need,” explained Dr. Upal Basu Roy, Director of Patient FoRCe. “LUNGevity is the only organization driving this type of change for the lung cancer community, and we anticipate that our findings will shape the future of lung cancer care.”

    For more information about Patient FoRCe, visit www.LUNGevity.org/patientforce.

    Click here to read the full press release.

  14. A market research company has asked us to share a survey opportunity for patients within the US with Stage IV lung cancer. Those who qualify and complete the 60-minute telephone survey will be compensated if you complete the screener and telephone interview. To see if you qualify for this survey, click here www.alphadetail.com/lcpatientstudy

    Please note: you will only be compensated for completing this in its entirety once. If you need any additional information please contact Elizabeth Lawson (ELawson@us.imshealth.com)

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.